Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 20/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3433922 | 1.00 | PTGER1 (0.68) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL15655080 | 0.94 | PTGER1 (0.60) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL10053828 | 0.94 | PTGER1 (0.60) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL252598 | 0.85 | PTGER1 (0.69) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4091451 | 0.81 | PTGER1 (1.00) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4096704 | 0.81 | PTGER1 (0.89) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4096456 | 0.81 | PTGER1 (0.64) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4091313 | 0.81 | PTGER1 (0.85) | PTGER1CYP1A2 | |
| SCHEMBL13693293 | 0.80 | PTGER1 (1.00) | PTGER1CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL4091254 | 0.80 | PTGER1 (0.83) | PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2945932-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2588459-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9394284-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| EP-2945932-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8859606-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2014113814-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20140121258-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-20130253028-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8492424-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120165382-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121258-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885CYP2C9 636/4885CYP1A2 413/4885 |
| US-20120165382-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885 |
| US-20150080446-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885 |
| US-20130131135-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885 |
| US-20130253028-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, CNR1 | PTGER1 1/4885CYP2C9 806/4885CYP1A2 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.